Snapshot from Aug 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Fennec Q2 2026 Results Announcement
Business earnings call

Fennec Q2 2026 Results Announcement

Analysis based on 6 articles · First reported Aug 05, 2026 · Last updated Aug 05, 2026

Sentiment
0
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The upcoming earnings release may influence Fennec's stock price as investors assess the company's financial performance and commercial progress of PEDMARK/PEDMARQSI. The announcement itself is routine and unlikely to cause significant market movement, but the results could provide insights into revenue growth and market expansion.

Pharmaceuticals
Event Summary

Fennec Pharmaceuticals Inc. announced on August 5, 2026 that it will release its second quarter 2026 financial results before the U.S. market opens on Tuesday, August 11, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the company's financial and business results. The announcement also recaps Fennec's product PEDMARK, which received FDA approval in September 2022, International — European Commission approval in June 2023, and U.K. approval in October 2023 under the brand name PEDMARQSI. In March 2024, Fennec entered into an exclusive licensing agreement with Norgine Pharmaceuticals Ltd. to commercialize PEDMARQSI in Europe, the U.K., Australia, and New Zealand. PEDMARK has Orphan Drug Exclusivity in the U.S., and PEDMARQSI has Pediatric Use Marketing Authorization in Europe, with patents protecting PEDMARK until 2039.

Key Actions
80 United States — Food and Drug Administration approved PEDMARK Fennec Pharmaceuticals
70 Fennec Pharmaceuticals entered licensing agreement Norgine
70 International — European Commission approved PEDMARQSI Fennec Pharmaceuticals
60 United Kingdom approved PEDMARQSI Fennec Pharmaceuticals
20 Fennec Pharmaceuticals announced financial results release
Entities Involved
stock
Fennec Pharmaceuticals
Fennec is the central entity, announcing its Q2 2026 earnings release and conference call. The event is routine, but the results may affect its stock price.
Importance 100.0 Sentiment 0.0
priv
Norgine
Norgine is Fennec's licensing partner for PEDMARQSI commercialization in Europe, U.K., Australia, and New Zealand. The event does not directly impact Norgine, but its partnership is part of Fennec's business update.
Importance 30.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA approved PEDMARK in September 2022, which is a key regulatory milestone for Fennec. This event does not involve new FDA actions.
Importance 20.0 Sentiment 0.0
govactor
International — European Commission
The International — European Commission approved PEDMARQSI in June 2023, enabling European commercialization. No new regulatory actions are part of this event.
Importance 20.0 Sentiment 0.0
cnt
United Kingdom
The U.K. approved PEDMARQSI in October 2023, allowing marketing in the U.K. This event does not involve new U.K. regulatory actions.
Importance 20.0 Sentiment 0.0
cnt
United States
The U.S. is Fennec's home market where PEDMARK is approved and commercialized. The earnings release will reflect U.S. performance.
Importance 15.0 Sentiment 0.0
cnt
Australia
Australia is one of the territories where Norgine has commercialization rights for PEDMARQSI. No direct impact from this event.
Importance 10.0 Sentiment 0.0
cnt
New Zealand
New Zealand is another territory covered by the Norgine licensing agreement. No direct impact from this event.
Importance 10.0 Sentiment 0.0
per
Robert Andrade
Robert Andrade is Fennec's CFO and the contact for investor inquiries. He will likely participate in the earnings call.
Importance 10.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ International — European Commission
United States — Food and Drug Administration related ↔ United Kingdom
United States — Food and Drug Administration related ↔ United States
United States — Food and Drug Administration related ↔ Australia
International — European Commission related ↔ United Kingdom
International — European Commission related ↔ United States
International — European Commission related ↔ Australia
United Kingdom allies ↔ United States The United Kingdom views the United States as its indispensable defense ally and a major trade partner, despite recent d
United Kingdom allies ↔ Australia The United Kingdom considers Australia a vital strategic partner in the Indo-Pacific, bound by the AUKUS nuclear submari
United Kingdom related ↔ New Zealand
United States related ↔ Australia
United States related ↔ New Zealand
Australia allies ↔ New Zealand Australia views New Zealand as a deeply integrated and strategic ally, sharing strong historical, cultural, economic, an
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.